Background: Although the significance of apolipoprotein E4 (Apo E4) in Alzheimer's disease (AD) has been well established in Caucasian populations, its role in determining the rate of cognitive decline in other ethnic groups has yet to be determined This study examined the two-year progression of cognitive decline and its association with Apo E4 allelic status in a group of Chinese elderly subjects with AD.
Method: One hundred andfour Chinese subjects with mild and moderate AD as assessed by the Clinical Dementia Rating (CDR 1 and 2) were followed up at a mean (SD) duration of 22.53 (5.21) months. The rate of cognitive decline and its association with Apo E4 allelic status was evaluated.
Results: At follow-up, 74 (73 percent) subjects were reassessed. Forty-nine remained stable at the same CDR and 25 had deteriorated The mean (SD) deterioration in the Mini-Mental State Examination (MMSE) was 2.52 (4.38) and in the Mattis Dementia Rating Scale (DRS) was 9.03 (14.98) (paired t-test, p < 0. 001). There was no significant difference in the baseline MMSE and DRS scores between the “stable,” “deteriorated,” or “deceased” groups. Mildly demented subjects with the Apo E4 allele were more likely to have deteriorated to a more severe CDR than subjects without the Apo E4 allele (Pearson χ2 = 5.72, df 1, p = 0.017, Odds ratio = 6.3, CI 1.3 to 30.53).
Conclusion: The presence of the Apo E4 allele may influence the rate ofcognitive deterioration, particularly in subjects with mildAD.
1. Liu L, Guo XE, Zhou YQ, et al.: Prevalence of dementia in China. Dement Geriatr Cogn Disord. 2003; 15: 226-230.
2.
2. Knopman DS, Boeve BF, Petersen RC: Essentials of the proper diagnoses of mild cognitive impairment, dementia, and major subtypes of dementia. Mayo Clin Proc. 2003; 78: 1290-1308.
3.
3. Stern RG, Mohs RC, Davidson M, et al.: A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration. Am JPsychiatry. 1994; 151: 390-396.
4.
4. Schmeidler J, Mohs RC, Aryan M: Relationship of disease severity to decline on specific cognitive and functional measures in Alzheimer disease. Alzheimer Dis Assoc Disord. 1998; 12: 146-151.
5.
5. Small BJ, Herlitz A, Fratiglioni L, et al.: Cognitive predictors of incident Alzheimer's disease: A prospective longitudinal study. Neuropsychology. 1997; 11: 413-420.
6.
6. Albert MS, Moss MB, Tanzi R, et al.: Preclinical prediction of AD using neuropsychological tests. JIntNeuropsych Soc. 2001; 78: 631-639.
7.
7. Chen P, Ratcliff G, Belle SH, et al.: Patterns of cognitive decline in presymptomatic Alzheimer's disease: A prospective community study. Arch Gen Psychiatry. 2001; 58: 853-858.
8.
8. Ercoli LM, Siddarth P, Dunkin JJ, et al.: MMSE items predict cognitive decline in persons with genetic risk for Alzheimer's disease. J Geriatr Psychiatry Neurol. 2003; 16: 67-73.
9.
9. Faber-Langendoen K, Morris JC, Knesevich JW, et al.: Aphasia in senile dementia of the Alzheimer type. Ann Neurol. 1988; 23: 365-370.
10.
10. Boller F, Becker JT, Holand AL, et al.: Predictors of decline in Alzheimer's disease. Cortex. 1991; 27: 9-17.
11.
11. Eslinger PJ, Swan GE, Carmelli D: Changes in Mini-Mental State Exam in community-dwelling older persons over 6 years: Relationship to health and neuropsychological measures. Neuroepidemiology. 2003; 22: 23-30.
12.
12. Holtzer R, Wegesin DJ, Albert SM, et al.: The rate of cognitive decline and risk of reaching clinical milestones in Alzheimer's disease. Arch Neurol. 2003; 60: 1137-1142.
13.
13. Burns A, Jacoby R, Levy R: Progression of cognitive impairment in Alzheimer's disease. JAm Geriatr Soc. 1991; 39: 39-45.
14.
14. Hui JS, Wilson RS, Bennett DA, et al.: Rate of cognitive decline and mortality in Alzheimer's disease. Neurology. 2003; 61: 1356-1361.
15.
15. Wilson RS, Beckett LA, Bienias JL, et al.: Terminal decline in cognitive function. Neurology. 2003; 60: 1782-1787.
16.
16. Mayeux R, Stern Y, Ottman R, et al. The apolipoprotein epsilon 4 allele in patients with Alzheimer's disease. Ann Neurol. 1993; 34: 752-754.
17.
17. Poirier J, Davignon J, Boutillier D, et al.: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993; 342(8873): 697-699.
18.
18. Li G. Silverman JM, Altstiel LD, et al.: Apolipoprotein E-epsilon 4 allele and familial risk in Alzheimer's disease. Genet Epidemiol. 1996; 13: 285-298.
19.
19. Burlinson S, Burns A, Mann D, et al.: Effect of apolipoprotein E status on clinical features of dementia. IntJGeriatr Psychiatry. 1998; 13: 177-185.
20.
20. Mak YT, Chiu H, Woo J, et al.: Apolipoprotein E genotype and Alzheimer's disease in Hong Kong elderly Chinese. Neurology. 1996; 46: 146-149.
21.
21. Poirier J: Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann N YAcadSci. 2000; 924: 81-90.
22.
22. Bennett DA, Wilson RS, Schneider JA, et al.: Apolipoprotein E epsilon 4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology. 2003; 60: 246-252.
23.
23. Petersen RC, Smith GE, Ivnik RJ, et al.: Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memoryimpaired individuals. JAMA. 1995; 273: 1274-1278.
24.
24. Lange KL, Bondi MW, Salmon DP, et al.: Decline in verbal memory during preclinical Alzheimer's disease Examination of the effects of APOE genotype. JInt Neuropsychol Sci. 2002; 8: 943-955.
25.
25. Bretsky P, Guralnik JM, Launer L, et al.: The role of Apo-E epsilon 4 in longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology. 2003; 60: 1077-1081.
26.
26. Lavretsky H, Ercoli L, Siddarth P, et al.: Apolipoprotein epsilon 4 allele status, depressive symptoms, and cognitive decline in middleaged and elderly persons without dementia. Am J Geriatr Psychiatry. 2003; 11: 667-673.
27.
27. Holmes C, Levy R, McLoughlin DM, et al.: Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. JNeurol Neurosurg Psychiatry. 1996; 61: 580-583.
28.
28. Kurz A, Egensperger R, Haupt M, et al.: Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology. 1996; 47: 440-443.
29.
29. Murphy GM Jr, Taylor J, Kraemer HC, et al.: No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Am JPsychiatry. 1997; 154: 603-608.
30.
30. Dal Forno G. Carson KA, Brookmeyer R, et al.: APOE genotype and survival in men and women with Alzheimer's disease. Neurology. 2002; 58: 1045-1050.
31.
31. Scarmeas N, Brandt J, Albert M, et al.: Association between the APOE genotype and psychopathological symptoms in Alzheimer's disease. Neurology. 2002; 58: 1182-1188.
32.
32. Hirono N, Hashimoto M, Yasuda M, et al.: Accelerated memory decline in Alzheimer's disease with apolipoprotein epsilon E allele. J Neuropsychiatry Clin Neurosci. 2003; 15: 354-358.
33.
33. Ewbank DC: The APOE gene and differences in life expectancy in Europe. J GerontolA Biol Sci Med Sci. 2004; 59: 16-20.
34.
34. Hong Kong 2001 Population Census Thematic Report-Older Persons. Hong Kong Special Administrative Region: Census and Statistics Department, 2002.
35.
35. McKhann G. Drachman D, Folstein M, et al.: Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34: 939-944.
36.
36. Hughes CP, Berg L, Danziger WL, et al.: A new clinical scale for the staging of dementia: Br J Psychiatry. 1982; 140: 556-572.
37.
37. Morris JC: Clinical dementia rating: A reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeratr. 1997; 9(suppl 1): 173-176.
38.
38. Mattis S: Mental status examination for organic mental syndrome in the elderly patient. In Geriatric Psychiatry. A Handbook for Psychiatrists and Primary Care Physicians. New York: Grune & Stratton, 1976.
39.
39. Chan AS, Choi MK, Salmon DP: The effects of age, education and gender on the Mattis Dementia Rating Scale performance of elderly Chinese and American individuals. J Gerontol B Psychol Soc Sci. 2001; 56: 356-363.
40.
40. Chan AS, Choi A, Chiu H, et al.: Clinical validity of the Chinese version of Mattis Dementia Rating Scale in differentiating dementia of Alzheimer's type in Hong Kong. J Int Neuropsychol Soc. 2003; 9: 45-55.
41.
41. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. JPsychiatr Res. 1975; 12: 189-198.
42.
42. Chiu HFK, Lee HC, Chung WS, et al.: Reliability and validity of the Cantonese version of the Mini-Mental State Examination-A preliminary study. J Hong Kong Coll Psychiatrists. 1994; 4(suppl 2): 25-28.
43.
43. Au A, Chan AS, Chiu H: Verbal learning in Alzheimer's dementia. JlntNeuropsychol Soc. 2003; 9: 363-375.
44.
44. Mok EHL, Lam LCW, Chiu HFK: Category verbal fluency test in Chinese subjects with Alzheimer's disease. Dement Geriatr Cogn Disord. 2004 (in press).
45.
45. Tsukamoto K, Watanabe T, Matsushima T, et al.: Determination by PRC-RFLP of apo E genotype in a Japanese population. J Lab Clin Med1993; 121:598-602.
46.
46. Morris JC, Edland S, Clark C, et al.: The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993; 43: 2457-2465.
47.
47. Han L, Cole M, Bellavance F, et al.: Tracking cognitive decline in Alzheimer's disease using the Mini-Mental State Examination: A meta-analysis. Int Psychogeriatr. 2000; 12: 231-247.
48.
48. Holmes C, Lovestone S. Long-term cognitive and functional decline in late onset Alzheimer's disease: Therapeutic implications. Age Ageing. 2003; 32: 200-204.
49.
49. Storandt M, Grant EA, Miller JP, et al.: Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology. 2002; 59: 1034-1041.
50.
50. Doraiswamy PM, Leon J, Cummings JL, et al.: Prevalence and impact of medical comorbidity in Alzheimer's disease. J Gerontol A BiolSciMedSci. 2002; 57: M173-M177.
